Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Kiniksa Pharmaceuticals stock

Learn how to easily invest in Kiniksa Pharmaceuticals stock.

Kiniksa Pharmaceuticals Ltd is a biotechnology business based in the US. Kiniksa Pharmaceuticals shares (KNSA) are listed on the NASDAQ and all prices are listed in US Dollars. Kiniksa Pharmaceuticals employs 168 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Kiniksa Pharmaceuticals

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – KNSA – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Kiniksa Pharmaceuticals stock price (NASDAQ: KNSA)

Use our graph to track the performance of KNSA stocks over time.

Kiniksa Pharmaceuticals shares at a glance

Information last updated 2022-01-26.
Latest market close$10.90
52-week range$9.96 - $24.70
50-day moving average $12.10
200-day moving average $13.15
Wall St. target price$28.60
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-2.56

Buy Kiniksa Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
M1 Finance
Free 1-year trial of M1 Plus
when you sign up for M1 Finance
Invest in your favorite stocks or in curated portfolios with automatic rebalancing.
SoFi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in most equities.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$10 of crypto
Open an account with access to crypto
A platform built for all kinds of traders and all styles of trading
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Stash Invest
Stocks, ETFs
$1 per month
Add at least $5 to your Invest account
Stash is more than an investment app. You’ll have access to tools that can help you become a confident investor.
Stocks, ETFs, Cryptocurrency
$0 per month
Download and sign up with; approved accounts receive a free stock slice worth up to $300, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Kiniksa Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Kiniksa Pharmaceuticals price performance over time

Historical closes compared with the close of $10.9 from 2022-01-25

1 week (2022-01-19) -1.62%
1 month (2021-12-23) -17.05%
3 months (2021-10-26) 2.83%
6 months (2021-07-26) -22.97%
1 year (2021-01-26) -44.73%
2 years (2020-01-24) -25.44%
3 years (2019-01-25) 22.37
5 years (2017-01-22) N/A

Kiniksa Pharmaceuticals financials

Revenue TTM $19.8 million
Gross profit TTM $0
Return on assets TTM -34.01%
Return on equity TTM -61.22%
Profit margin 0%
Book value $3.11
Market capitalisation $750.9 million

TTM: trailing 12 months

Kiniksa Pharmaceuticals share dividends

We're not expecting Kiniksa Pharmaceuticals to pay a dividend over the next 12 months.

Kiniksa Pharmaceuticals share price volatility

Over the last 12 months, Kiniksa Pharmaceuticals's shares have ranged in value from as little as $9.96 up to $24.7. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Kiniksa Pharmaceuticals's is -0.0986. This would suggest that Kiniksa Pharmaceuticals's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Kiniksa Pharmaceuticals has bucked the trend.

Kiniksa Pharmaceuticals overview

Kiniksa Pharmaceuticals, Ltd. , a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its product candidates include Rilonacept, which is in Phase III clinical trials for the treatment of recurrent pericarditis, an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody that is in Phase II clinical trials for the treatment of giant cell arteritis; and Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition. The company's preclinical product candidates comprise KPL-404, a monoclonal antibody inhibitor of the CD40/CD40L interaction, a central control node of T-cell-dependent, and B-cell-mediated humoral adaptive immunity. The company has a clinical collaboration with Kite Pharma, Inc. to evaluate the combination of Yescarta and Mavrilimumab in patients with relapsed or refractory Large B-Cell lymphoma. Kiniksa Pharmaceuticals, Ltd.

Frequently asked questions

What percentage of Kiniksa Pharmaceuticals is owned by insiders or institutions?
Currently 4.187% of Kiniksa Pharmaceuticals shares are held by insiders and 89.271% by institutions.
How many people work for Kiniksa Pharmaceuticals?
Latest data suggests 168 work at Kiniksa Pharmaceuticals.
When does the fiscal year end for Kiniksa Pharmaceuticals?
Kiniksa Pharmaceuticals's fiscal year ends in December.
Where is Kiniksa Pharmaceuticals based?
Kiniksa Pharmaceuticals's address is: Clarendon House, Hamilton, Bermuda, HM 11
What is Kiniksa Pharmaceuticals's ISIN number?
Kiniksa Pharmaceuticals's international securities identification number is: BMG5269C1010
What is Kiniksa Pharmaceuticals's CUSIP number?
Kiniksa Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: G5269C101

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site